Skip to main content
. 2007 Jul 15;21(14):1714–1719. doi: 10.1101/gad.1549407

Figure 2.

Figure 2.

IL6−/− mice are resistant to carcinogen-induced skin tumors. Fourteen IL6+/+ and 15 IL6−/− mice were treated with a single topical application of DMBA, followed 1 wk later by twice-weekly topical applications of TPA for 20 wk to induce skin tumors. (A) Reduction of spontaneous tumors in IL6−/− mice. Representative mice of the indicated genotype at 20 wk. (Arrows) Tumors. (B) Reduction in the number of IL6−/− mice having tumors. Percentage of IL6+/+ (open box) and IL6−/− (red box) mice with tumors versus time after initial application of DMBA (weeks). (C) Reduction in the number of tumors in IL6−/− mice. Mean number of tumors per IL6+/+ (open box) and IL6−/− (red box) mouse versus time after initial application of DMBA (weeks). (**) P < 0.01 (D) Reduction in tumor volume in IL6−/− mice. Mean tumor volume per IL6+/+ (open box) and IL6−/− (red box) mouse versus time after initial application of DMBA (weeks). (*) P < 0.05.